SY   HUDEP2; Human Umbilical cord blood-Derived Erythroid Progenitor-2
DR   BioGRID_ORCS_Cell_line; 1800
DR   PRIDE; PXD030182
DR   RCB; RCB4557
DR   Wikidata; Q54896730
RX   Patent=US8975072;
RX   PubMed=23533656;
RX   PubMed=31164570;
RX   PubMed=31753923;
RX   PubMed=35269949;
CC   Population: Japanese.
CC   Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells.
CC   Doubling time: 22.7 +- 5.0 hours (PubMed=31753923).
CC   Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6.
CC   Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7.
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: Please contact directly Dr. Nakamura Y. for the use of this cell line (
CC   Derived from site: In situ; Umbilical cord blood; UBERON=UBERON_0012168.
CC   Cell type: Erythroid progenitor cell; CL=CL_0000038.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   <1D
CA   Transformed cell line
DT   Created: 14-05-18; Last updated: 30-01-24; Version: 14
RX   Patent=US8975072;
RA   Nakamura Y., Kurita R.;
RT   "Human erythroid progenitor cell line comprising HPV E6/E7 operably
RT   linked to an inducible promoter and method for producing human
RT   enucleated red blood cells.";
RL   Patent number US8975072, 10-Mar-2015.
RX   PubMed=23533656; DOI=10.1371/journal.pone.0059890;
RA   Kurita R., Suda N., Sudo K., Miharada K., Hiroyama T., Miyoshi H.,
RA   Tani K., Nakamura Y.;
RT   "Establishment of immortalized human erythroid progenitor cell lines
RT   able to produce enucleated red blood cells.";
RL   PLoS ONE 8:E59890-E59890(2013).
RX   PubMed=31164570; DOI=10.3390/mps1030028;
RA   Moir-Meyer G., Cheong P.L., Olijnik A.-A., Brown J., Knight S.,
RA   King A., Kurita R., Nakamura Y., Gibbons R.J., Higgs D.R., Buckle V.J.,
RA   Babbs C.;
RT   "Robust CRISPR/Cas9 genome editing of the HUDEP-2 erythroid precursor
RT   line using plasmids and single-stranded oligonucleotide donors.";
RL   Methods Protoc. 1:28.1-28.17(2018).
RX   PubMed=31753923; DOI=10.3324/haematol.2019.229211;
RA   Daniels D.E., Downes D.J., Ferrer-Vicens I., Ferguson D.C.J.,
RA   Singleton B.K., Wilson M.C., Trakarnsanga K., Kurita R., Nakamura Y.,
RA   Anstee D.J., Frayne J.;
RT   "Comparing the two leading erythroid lines BEL-A and HUDEP-2.";
RL   Haematologica 105:E389-E394(2020).
RX   PubMed=35269949; DOI=10.3390/ijms23052807;
RA   Zhou G.-Q., Zhang H.-K., Lin A.-N., Wu Z., Li T., Zhang X.-M.,
RA   Chen H.-Y., Lu D.-R.;
RT   "Multi-omics analysis in beta-thalassemia using an HBB gene-knockout
RT   human erythroid progenitor cell model.";
RL   Int. J. Mol. Sci. 23:2807.1-2807.14(2022).